Skip to content Skip to footer
Subscribe Now
NEWS

CervoMed Completes Patient Enrollment in P-IIa Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia

Shots: CervoMed has completed enrollment in the P-IIa study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia, with interim results to be presented at CTAD 2026 The study will evaluate the safety, PK, & clinical effects of neflamapimod (40mg, PO, TID; n=19 and 80mg, BID; n=6)…
July 9, 2026

Read more

NEWS

Denali Regains Full Rights to Frontotemporal Dementia Therapy as Takeda Exits DNL593 Pact

Shots: Takeda has terminated its collaboration with Denali for the co-development & commercialization of DNL593, citing strategic considerations unrelated to safety or efficacy Denali will regain full control of DNL593, a progranulin replacement therapy leveraging its Protein TransportVehicle platform to cross the blood-brain barrier for the treatment of frontotemporal dementia The ongoing P-I/II study has…
April 6, 2026

Read more

NEWS

Transition Bio Inks ~$500M Pact with Voyager Therapeutics to Develop Small Molecules for Neurodegenerative Diseases

Shots: Transition Bio has entered into a drug discovery collaboration & license option agreement with Voyager Therapeutics to identify & develop selective small molecules targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS) & frontotemporal dementia As per the deal, Transition Bio will discover & optimize TDP-43–targeting small molecules, after which Voyager may license exclusive global…
November 11, 2025

Read more